Expanding the Arsenal of Clinically Active <i>KRAS</i> G12C Inhibitors
Authors: Kathryn C. Arbour, Piro Lito
Journal: Journal of Clinical Oncology (2022)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). February 15, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.00562 Journal of Clinical Oncology - published online before print June 28, 2022 PMID: 35763705 Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors Kathryn C. Arbour , MD1,2xKathryn C. ArbourSearch for articles by this author and Piro Lito , MD, PhD1,2,3xPiro LitoSearch for articles by this author Show More 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY2Department of Medicine, Weill Cornell Medical College, New York, NY3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY https://doi.org/10.1200/JCO.22.00562 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTP.L. is supported in part by the NIH/NCI (1R01CA23074501 and 1R01CA23026701A1), The Pew Charitable Trusts, and the Damon Runyon Cancer Research Foundation. K.C.A. is supported in part by a Career Development Award from the LUNGevity foundation.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTExpanding the Arsenal of Clinically Active KRAS G12C InhibitorsThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Kathryn C. ArbourConsulting or Advisory Role: SanofiResearch Funding: Mirati Therapeutics (Inst), Genentech (Inst)Piro LitoLeadership: Frontier MedicinesConsulting or Advisory Role: Black Diamond Therapeutics, Repare Therapeutics, AmMax Bio, Revolution MedicinesSpeakers' Bureau: Boehringer IngelheimResearch Funding: Mirati Therapeutics (Inst), Revolution Medicines (Inst), Amgen (Inst), Boehringer Ingelheim (Inst), Virtec pharmaceuticals (Inst)Patents, Royalties, Other Intellectual Property: I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat BRAF mutant cancers (Inst), I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat KRAS mutant cancers (Inst)No other potential conflicts of interest were reported. Companion First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)